Novavax, Inc. (NVAX)
Thursday, November 5, 2026
Key stats
Chart
Price, buy and sell signals and key levels on one chart.
Past 1Y
MA21MA180
SignalsBuyEarly buySellEarly sellTurning pointsSwing highSwing low
Up dayDown day
Thursday, November 5, 2026
Price, buy and sell signals and key levels on one chart.
Novavax (NVAX) closed at $7.48 on Jul 30, 2026, up 1.9% on the day. The stock is down 20.6% over the past month, down 6.1% over three months, up 11.3% year to date and up 9.2% over the past year (since Jul 30, 2025). It trades 37.5% below its 52-week high of $11.97 and 20.6% above its 52-week low of $6.20. The close sits below its 50-day moving average ($9.02) and below its 200-day moving average ($8.48).
NVAX is scheduled to report earnings on Nov 5, 2026, before market open.
Novavax is scheduled to report on Nov 5, 2026, before market open.
No — the Jul 30, 2026 close of $7.48 is 11.8% below the 200-day average of $8.48.
NVAX closed 37.5% below its 52-week high of $11.97.
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.